Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli
Metadatos
Afficher la notice complèteAuteur
Solorzano Puerto, Antonio; Gutiérrez Fernández, José; Romero, José María; Luna Del Castillo, Juan De Dios; Damas, Miguel; Piédrola Angulo, GonzaloEditorial
Wiley
Materia
Escherichia coli ESBLs Microdilution Susceptibility
Date
2007-10Referencia bibliográfica
Sorlózano A, Gutiérrez J, Romero JM, de Dios Luna J, Damas M, Piédrola G. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli. J Basic Microbiol. 2007 Oct;47(5):413-6. https://doi.org/10.1002/jobm.200710318
Résumé
Twelve beta-lactam and non-beta-lactam antibiotics were evaluated against 115 clinical isolates of extended-spectrum beta-lactamase-producing (ESBLs) Escherichia coli using a broth microdilution test in accordance with the CLSI guidelines. Susceptibility was 100% with imipenem, ertapenem and amikacin, 95.7% with piperacillin-tazobactam, 91.3% with cefoxitin, 87% with tobramycin, 81.7% with amoxicillin-clavulanate, 80% with cefepime, 67.8% with ceftazidime, 27.8% with ciprofloxacin, 27% with levofloxacin and 13% with ceftriaxone. Ertapenem was the antibiotic with the lowest minimum inhibitory concentrations (MICs) for all isolates. There were no clinically relevant differences in the activity of the antibiotics in the presence of CTX-M-9 or SHV enzymes.